Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).

被引：0
|
作者：
Armstrong, Andrew J.
Halabi, Susan
Healy, Patrick
Alumkal, Joshi J.
Yu, Evan Y.
Winters, Carolyn
Hobbs, Carey
Soleau, Colleen
Slottke, Rachel
Mundy, Kelly
George, Daniel J.
机构：
[1] Duke Univ, Duke Canc Inst, Durham, NC USA
[2] Duke Univ Med Ctr, Durham, NC USA
[3] OHSU, Portland, OR USA
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[5] Duke Univ, Durham, NC USA
[6] Duke Canc Inst, Durham, NC USA
[7] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.5025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5025
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
    Armstrong, Andrew J.
    Halabi, Susan
    Healy, Patrick
    Alumkal, Joshi J.
    Winters, Carolyn
    Kephart, Julie
    Bitting, Rhonda L.
    Hobbs, Carey
    Soleau, Colleen F.
    Beer, Tomasz M.
    Slottke, Rachel
    Mundy, Kelly
    Yu, Evan Y.
    George, Daniel J.
    EUROPEAN JOURNAL OF CANCER, 2017, 81 : 228 - 236
  • [2] Discovery of BKM120, a pan class I PI3 kinase inhibitor in phase I/II clinical trials
    Burger, Matthew T.
    Pecchi, Sabina
    Wagman, Allan
    Ni, Zhi-Jie
    Knapp, Mark
    Atallah, Gordana
    Pfister, Keith
    Ng, Simon
    Smith, Aaron
    Pick, Teresa
    Frazier, Kelly
    Verhagen, Joelle
    Zhang, Yanchen
    Bartulis, Sarah
    Hendricksen, Tom
    Iwanowicz, Edwin
    Hazenadar, Joshua
    Huh, Kay
    Ashash, Ahmad
    Xin, Xiaohua
    Menezes, Daniel
    Merritt, Hanne
    Wiesmann, Marion
    Voliva, Charles
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [3] A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC).
    Gopalakrishnan, Dharmesh
    Kirk, Jason
    Davis, John
    George, Saby
    Levine, Ellis Glenn
    Beumer, Jan Hendrik
    Appleman, Leonard Joseph
    Tang, Dean
    Chatta, Gurkamal S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Phase 2 study of the pan-isoform PI3 kinase inhibitor BKM120 in metastatic urothelial carcinoma patients.
    Iyer, Gopa
    Tully, Christopher Michael
    Garcia-Grossman, Ilana Rebecca
    Scott, Sasinya N.
    Boyd, Mariel Elena
    Mccoy, Asia S.
    Berger, Michael F.
    Al-Ahmadie, Hikmat
    Solit, David B.
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [5] Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM)
    Wen, Patrick Y.
    Yung, W. K. Alfred
    Mellinghoff, Ingo K.
    Lamborn, Kathleen
    Ramkissoon, Shakti
    Cloughesy, Timothy Francis
    Rinne, Mikael
    Omuro, Antonio Marcilio Padula
    DeAngelis, Lisa Marie
    Gilbert, Mark R.
    Chi, Andrew S.
    Batchelor, Tracy
    Colman, Howard
    Chang, Susan Marina
    Massacesi, Cristian
    DiTomaso, Emmanuelle
    Prados, Michael
    Reardon, David A.
    Ligon, Keith L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC)
    Serritella, Anthony
    Shevrin, Daniel H.
    Heath, Elisabeth I.
    Wade, James Lloyd
    Martinez, Elia
    Karrison, Theodore
    Stadler, Walter Michael
    Szmulewitz, Russell Zelig
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa Maria
    Bassi, Sunakshi
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [8] Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC)
    Cetnar, J. P.
    Rosen, M. A.
    Vaughn, D. J.
    Haas, N. B.
    Troxel, A. B.
    Song, H.
    Adluru, G.
    Flaherty, K. T.
    O'Dwyer, P. J.
    Amaravadi, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] PHASE 3 TRIAL OF PEMBROLIZUMAB AND ENZALUTAMIDE VERSUS ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) (KEYNOTE-641)
    Graff, Julie Nicole
    Burgents, Joseph
    Liang, Li Wen
    Stenzl, Arnulf
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A210 - A210
  • [10] Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC)
    Kim, Joseph W.
    McKay, Rana R.
    Taplin, Mary-Ellen
    Davis, Nancy B.
    Monk, Paul
    Appleman, Leonard Joseph
    Lara, Primo
    Vaishampayan, Ulka N.
    Zhang, Jingsong
    Paul, Asit K.
    Bubley, Glenn
    Van Allen, Eliezer Mendel
    Huang, Ying
    Zhang, Zhenwei
    Loda, Massimo
    Shapiro, Geoffrey
    LoRusso, Patricia
    Ivy, S. Percy
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345